Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 54.4%

Neg 54.4% Neu 0% Pos 0%

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $24 to $15.